2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2010
Botulinum Toxin A for Treatment of Allodynia of Complex Regional Pain Syndrome: A Pilot Study
Safarpour D, Salardini A, Richardson D, Jabbari B. Botulinum Toxin A for Treatment of Allodynia of Complex Regional Pain Syndrome: A Pilot Study. Pain Medicine 2010, 11: 1411-1414. PMID: 20609130, DOI: 10.1111/j.1526-4637.2010.00897.x.Peer-Reviewed Original ResearchConceptsComplex regional pain syndromeRegional pain syndromeBotulinum toxin APain syndromeToxin AOpen-label protocolPain Impact QuestionnairePlacebo-controlled protocolTreatment of allodyniaBrief Pain InventoryMcGill Pain QuestionnaireGlobal satisfaction scaleAllodynic areaAllodynic skinPain InventoryPain QuestionnaireImpact QuestionnaireSubcutaneous administrationPatientsSatisfaction ScaleAllodyniaPilot studySyndromeBoNTTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply